Form 4: Waters Corp Grants SVP Equity Awards

Waters Corporation's SVP of Advanced Diagnostics, Jianqing Bennett, received 986 restricted stock units and 4,826 stock options as part of compensation.

Summary

• Jianqing Bennett, SVP Waters Adv. Diagnostics at Waters Corp (WAT), acquired 986 restricted stock units (RSUs) and 4,826 stock options.
• The RSUs will vest in four equal annual installments, with the first vesting on February 25, 2027, contingent on continued service.
• The stock options have an exercise price of $319.44 and will vest in four equal annual installments, with the first exercisable on February 25, 2027.
• The stock options expire on February 25, 2036.
• Following these transactions, Bennett beneficially owns 7,244 shares of common stock (including RSUs) and 4,826 stock options directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retention and aligning management incentives with long-term shareholder value.

Positives

• The grant of 986 restricted stock units and 4,826 stock options aligns the executive's interests with long-term shareholder value.
• The vesting schedule, with the first installment on February 25, 2027, promotes executive retention and continued service.

Negatives

• No specific negatives are identified in this routine insider transaction report.

Risks

• No specific risks to the company are detailed in this Form 4 filing.

Future Outlook

The vesting schedules for the RSUs and stock options extend into the future, indicating a long-term incentive structure for the executive.

Management Comments

• No direct management comments or notable quotes are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that equity grants to senior executives like Jianqing Bennett are a standard practice in the life sciences and diagnostics industry, aiming to incentivize performance and ensure long-term alignment with company goals. This type of compensation is crucial for attracting and retaining top talent in a competitive sector.

Comparison to Industry Standards

• Executive equity compensation packages, including RSUs and stock options with multi-year vesting schedules, are common across the S&P 500 and particularly within the specialized instruments and diagnostics sector.
• Companies like Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR) frequently utilize similar structures to reward and retain key leadership, linking executive wealth creation to sustained company performance and shareholder returns.
• The specific grant size and exercise price would typically be benchmarked against peer groups to ensure competitiveness.

Related Party Transactions

• This filing details an equity compensation grant to a senior officer, which is a form of related party transaction.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares upon RSU vesting and option exercise, but also benefits from incentivized executive performance and retention.
• Employees: Reflects standard executive compensation practices, potentially setting a precedent or benchmark for other senior roles.
• Executive (Jianqing Bennett): Receives significant long-term equity incentives, aligning personal financial interests with the company's success.

Next Steps

• Vesting of restricted stock units in four equal annual installments, starting February 25, 2027.
• Vesting and exercisability of stock options in four equal annual installments, starting February 25, 2027.

Key Dates

Keywords

Waters Corp, WAT, Jianqing Bennett, SVP, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Form 4, Executive Compensation